Seeking Stability in Unpredictable Waters
Among the choppy seas of the financial world, discerning investors are seeking stability in uncertain times. Recent trends in the markets have shown a notable shift in investment preferences, prompting a reassessment of the best stocks to consider for April.
Sempra: Unexciting but Potentially Lucrative
Amidst the sea of volatility, the utility sector stands as a bastion of dependability. Enter Sempra (NYSE:SRE), a company that exudes a sense of boredom yet hides a potential for robust returns. Despite its unassuming nature, Sempra stands tall as a beacon of reliability. In the fiscal year of 2023, the company exhibited commendable performance, surpassing earnings expectations with an average surprise of 5.1% over four quarters.
Analysts project a positive outlook for the current fiscal year, estimating an earnings per share of $4.80 on revenues amounting to $16.79 billion. The company’s forward dividend yield of 3.45% further sweetens the deal, positioning SRE as a strong contender for the best stock picks in April.
Exxon Mobil: A Fossil Fuel Dinosaur or a Potential Gem?
In a world increasingly pivoting towards renewable energy, Exxon Mobil (NYSE:XOM) appears as a relic of a bygone era. Yet, the allure of high energy density inherent in fossil fuels ensures that Exxon’s flame continues to burn bright. Geopolitical tensions further bolster its position, with potential supply disruptions driving demand upwards amidst global uncertainties.
Despite a mixed bag in fiscal 2023 earnings estimates, the forecast for 2024 remains promising, with an anticipated EPS of $8.35 on revenues totaling $308.31 billion. Additionally, the company’s forward dividend yield of 3.27% adds another layer of appeal, making XOM a compelling choice among the top stock picks for April.
AbbVie: Pharma Powerhouse in the Healthcare Sector
Steering into the domain of healthcare, AbbVie (NYSE:ABBV) emerges as a prominent player in the pharmaceutical realm. Known for its diversified portfolio of offerings, including the widely recognized Humira for autoimmune diseases, AbbVie commands attention with its acquisition of Allergan, expanding its reach into the realm of cosmetic treatments.
Consistent performance is the hallmark of AbbVie, with a track record of meeting or exceeding EPS targets in the past year. Analysts foresee a positive trajectory for fiscal 2024, predicting an EPS of $11.19 on revenues amounting to $54.56 billion. The company’s forward dividend yield of 3.44% adds a layer of stability, positioning ABBV as a top contender among the best stock picks for April.
As the financial landscape continues to evolve, these stock picks offer a blend of stability, potential growth, and dividend allure, making them worthy considerations for investors looking to navigate the turbulent waters of the market.
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
